Allstate enters the final week of September in an awkward position: the stock has shed nearly 9% over seven sessions to $227.60, yet the options market is flashing one of its most bullish signals of the past year.
The options story is the standout this week. The put/call ratio has fallen sharply to 1.27, almost 2.2 standard deviations below its 20-day average of 1.45 — the most call-heavy skew Allstate has seen in months. For a stock that has spent most of the past 30 days with a PCR above 1.50, the sudden shift toward calls is striking. One reading: with the stock having already sold off hard, options buyers are positioning for a bounce rather than hedging further downside. The 52-week PCR range runs from 0.76 to 1.64, and the current print is well toward the bullish end of that band.
Short interest tells a far quieter story. Bears hold just 2.2% of the free float — a genuinely low level — and the week-on-week change is a negligible 0.6%. Nothing in the lending market supports a short-driven narrative here. The borrow market is deeply loose, with availability running at over 5,000% of existing short interest, meaning there are roughly 53 shares available in the lending pool for every one currently borrowed. Borrowing costs confirm the indifference: the cost to borrow is running at 0.47%, back near its cheapest levels of the summer. Shorts are not piling in.
The Street is more divided than those benign technicals might suggest. Analyst sentiment has turned cautious over the past six weeks. Citigroup downgraded to Sell after the Q2 print, raising its target modestly to $240 while stepping off Neutral. Keefe, Bruyette & Woods cut all the way to Underperform with a $250 target. Argus moved to Hold. Against that, Mizuho maintained Outperform and nudged its target to $300 last week, and JPMorgan kept Overweight at $292. The consensus mean target is $276 — roughly 21% above Friday's close — but with the stock down 12% on the month, that gap now includes a growing cluster of skeptics. Valuation multiples have compressed with the price: the P/E has pulled back by about a full point over 30 days to 7.6x, while price-to-book has slipped to 1.52x. Both remain modest for a name that scores in the 90th percentile on earnings surprise and 90th on EV/EBIT efficiency.
Insider activity adds a note of caution worth registering. Net selling over the past 90 days totals roughly $23.8 million across open-market transactions. The most material were from two executives in early August: John Dugenske sold around $8.9 million worth near $270, and Mario Rizzo sold approximately $14.9 million at similar prices. Both disposals were discretionary, with no 10b5-1 plan attached — a distinction that makes them harder to dismiss as routine. The stock has since retreated 15% from those execution prices, so the timing, in hindsight, looks prescient.
The peer group offers useful context for the week's selloff. HIG fell 5.8% over the same period, WRB dropped 4.5%, and PGR gave back 3.7%. So while Allstate's 9% decline is sharper, the whole P&C insurance complex has come under pressure — this is a sector move, not purely an Allstate-specific one. Earnings are scheduled for October 28, and with the prior two prints producing modest one-day moves (roughly +5% and flat), what the market focuses on next is less about catastrophe losses and more about whether the call-side positioning in options reflects genuine conviction — or simply a knee-jerk reaction to a stock that fell fast.
See the live data behind this article on ORTEX.
Open ALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
